Login
$GRI
$1.63 +$0.04 (2.85%) Close

Insider Transactions

What GRI Bio Inc's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.

Insider trades

3 months 12 months
Open-market buys 0 0
Sells 0 0
Total trades 0 0

Shares traded

3 months 12 months
Acquired 0 0
Disposed 0 0
Net activity +0 +0

See the story behind these numbers

View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.

Open-market buyer Disclosed 10b5-1 Heavy discretionary Sign up free

All transactions

Insider Relation Date Transaction Shares Price Value Shares held
Hertz Walter Marc Chief Executive Officer Apr 21 Grant / award · A +385,510 — — 385,510
Chaturvedi Vipin Chief Scientific Officer Apr 21 Grant / award · A +172,189 — — 172,189
Agro Albert Chief Medical Officer Apr 21 Grant / award · A +172,189 — — 172,189
Thorell Marella Director Dec 13 Other Transaction · J −28,517 — — 9,506
Thorell Marella Director Jul 01 Grant / award · A +38,023 — — 38,023
Kelly Leanne M. Chief Financial Officer Jun 04 Open-market buy · P +1,508 $4.08 +$6.15K 6,250
Kelly Leanne M. Chief Financial Officer Jun 03 Open-market buy · P +1,085 $4.05 +$4.39K 4,742
Kelly Leanne M. Chief Financial Officer Jun 02 Open-market buy · P +3,657 $4.00 +$14.6K 3,657
Payne Joseph E Director May 26 Open-market buy · P +6,800 $4.50 +$30.6K 17,500
Payne Joseph E Director May 25 Open-market buy · P +10,700 $3.85 +$41.2K 10,700
Baker David Charles Chief Executive Officer Feb 12 Open-market buy · P +1,000 $8.00 +$8K 8,843
Baker David Charles Chief Executive Officer Feb 12 Other Transaction · J +7,843 $6.40 +$50.2K 7,843
Salmon Pharma GmbH 10% owner Feb 12 Other Transaction · J +47,063 $6.40 +$301K 47,063
Ammer Richard Director Feb 12 Other Transaction · J +47,063 $6.40 +$301K 47,063

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support